Charles Lynde

14.2k total citations · 2 hit papers
282 papers, 7.8k citations indexed

About

Charles Lynde is a scholar working on Dermatology, Immunology and Epidemiology. According to data from OpenAlex, Charles Lynde has authored 282 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 185 papers in Dermatology, 101 papers in Immunology and 55 papers in Epidemiology. Recurrent topics in Charles Lynde's work include Dermatology and Skin Diseases (131 papers), Psoriasis: Treatment and Pathogenesis (93 papers) and Acne and Rosacea Treatments and Effects (37 papers). Charles Lynde is often cited by papers focused on Dermatology and Skin Diseases (131 papers), Psoriasis: Treatment and Pathogenesis (93 papers) and Acne and Rosacea Treatments and Effects (37 papers). Charles Lynde collaborates with scholars based in Canada, United States and Germany. Charles Lynde's co-authors include Aditya K. Gupta, Yves Poulin, Wayne Gulliver, Patrick Fleming, Richard C. Summerbell, Robert Bissonnette, Hem C. Jain, Ronald Vender, J. Kraft and Marc Bourcier and has published in prestigious journals such as The Lancet, Journal of Allergy and Clinical Immunology and Annals of the Rheumatic Diseases.

In The Last Decade

Charles Lynde

264 papers receiving 7.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis

2015 660 citations J. Kraft, Charles Lynde et al. profile →
Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial

2023 134 citations Brett King, Xingqi Zhang et al. profile →

Peers

Countries citing papers authored by Charles Lynde

Since Specialization

Citations

This map shows the geographic impact of Charles Lynde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Lynde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Lynde more than expected).

Fields of papers citing papers by Charles Lynde

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles Lynde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Lynde. The network helps show where Charles Lynde may publish in the future.

Co-authorship network of co-authors of Charles Lynde

This figure shows the co-authorship network connecting the top 25 collaborators of Charles Lynde. A scholar is included among the top collaborators of Charles Lynde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles Lynde. Charles Lynde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting IL-22RA1 with temtokibart: A novel approach in atopic dermatitis: Phase 2a monotherapy study results 2025 ·Journal of Allergy and Clinical Immunology ·Diamant Thaçi, Vivian Laquer, Charles Lynde, Adam Reich, Weily Soong, Margitta Worm, (unknown), (unknown), Thomas Litman, (unknown), Martin Olesen, Ole E. Sørensen, Melinda Gooderham	0
2	Efficacy and safety of ruxolitinib cream combined with narrow-band UVB phototherapy for treatment of vitiligo 2025 ·Journal of Investigative Dermatology ·Amit G. Pandya, Charles Lynde, (unknown), (unknown), (unknown), Lawrence J. Green, (unknown), (unknown), Deanna Kornacki, (unknown)	0
3	A Post Hoc Analysis of Atopic Dermatitis of the Head and Neck and Other Body Regions from the Amlitelimab STREAM-AD Phase 2b Study 2025 ·Dermatology and Therapy ·Adam Reich, Andrew Blauvelt, Stephan Weidinger, Vivian Y. Shi, Norito Katoh, Charles Lynde, Xing‐Hua Gao, Nicole M. Armstrong, Charlotte Bernigaud, (unknown)	0
4	Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months 2025 ·Dermatology and Therapy ·Diamant Thaçi, Mamitaro Ohtsuki, Julia‐Tatjana Maul, Andrea Szegedi, Paula Carolina Luna, Charles Lynde, Ahmed M. Soliman, Hongwei Wang, Christian Kaufmann, (unknown), (unknown), Simone Rubant, Kim Papp	5
5	62188 Amlitelimab Reduces Th2-, Th1-, and Th17/22-Related Cytokines and Chemokines in Adults With Moderate-to-Severe Atopic Dermatitis): Results From an Exploratory Analysis of the Phase 2b STREAM-AD Study 2025 ·Journal of the American Academy of Dermatology ·Bob Geng, Stephan Weidinger, Saeko Nakajima, Donald Y.M. Leung, Charles Lynde, Karl Yen, Junwen Deng, (unknown), (unknown)	0
6	Maintenance of Investigator’s Static Global Assessment Response with Once-Daily Crisaborole in Participants with Mild to Moderate Atopic Dermatitis 2024 ·Dermatology and Therapy ·Lawrence F. Eichenfield, Linda Stein Gold, Charles Lynde, Lyn Guenther, Shoshana Greenberger, Chia‐Yu Chu, (unknown), Bonnie Vlahos, Paul W. Sanders, Amy Cha, (unknown)	0
7	Considerations for defining and diagnosing generalized pustular psoriasis 2024 ·Journal of the European Academy of Dermatology and Venereology ·Vimal H. Prajapati, Charles Lynde, Melinda Gooderham, Chih-ho Hong, Mark G. Kirchhof, Perla Lansang, (unknown), Irina Turchin, Ronald Vender, Jensen Yeung, Kim Papp	4
8	53822 Longitudinal evaluation of the psoriasis epidemiology screening tool (PEST) in patients with moderate to severe psoriasis: Results from the PURE Registry 2024 ·Journal of the American Academy of Dermatology ·Lorne Albrecht, Jennifer Beecker, Isabelle Delorme, (unknown), (unknown), Charles Lynde, Kim Papp, Paul Keown, (unknown), (unknown), Philip Helliwell	0
9	Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis 2024 ·Journal of Allergy and Clinical Immunology ·Stephan Weidinger, Andrew Blauvelt, Kim Papp, Adam Reich, Chih‐Hung Lee, Margitta Worm, Charles Lynde, Yoko Kataoka, Peter Foley, Xiaodan Wei, Wanling Wong, (unknown), Christine Weber, (unknown), Sonya Davey, Fabrice Hurbin, (unknown), Karl Yen, John T. O’Malley, Charlotte Bernigaud	12
10	Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial 2023 ·Journal of the American Academy of Dermatology ·Joseph F. Merola, Lawrence Charles Parish, Lyn Guenther, Charles Lynde, J.‐P. Lacour, Petra Staubach, Sue Cheng, Maria Paris, Hernàn Picard, (unknown), (unknown), Mindy Chen, Kim Papp	13
11	The burden associated with generalized pustular psoriasis: A Canadian population-based study of inpatient care, emergency departments, and hospital- or community-based outpatient clinics 2023 ·JAAD International ·Jean‐Éric Tarride, Vimal H. Prajapati, Charles Lynde, Gord Blackhouse	6
12	Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials 2023 ·American Journal of Clinical Dermatology ·Jonathan I. Silverberg, Charles Lynde, Katrina Abuabara, Cataldo Patruno, Anna De Benedetto, Haixin Zhang, (unknown), (unknown), Faisal A. Khokhar, (unknown), (unknown), Noah A. Levit	12
13	Expert consensus on the systemic treatment of atopic dermatitis in special populations 2023 ·Journal of the European Academy of Dermatology and Venereology ·David N. Adam, Melinda Gooderham, Jennifer Beecker, (unknown), Carolyn Jack, (unknown), Perla Lansang, Charles Lynde, Kim Papp, Vimal H. Prajapati, Irina Turchin, Jensen Yeung	42
14	A Plain Language Summary on Ritlecitinib Treatment for Adults and Adolescents with Alopecia Areata 2023 ·Immunotherapy ·Brett King, Xingqi Zhang, (unknown), Jacek C. Szepietowski, Jerry Shapiro, Charles Lynde, Natasha Atanaskova Mesinkovska, Samuel H. Zwillich, Lynne Napatalung, Dalia Wajsbrot, Rana Fayyad, Amy Freyman, Debanjali Mitra, Vivek S. Purohit, Rodney Sinclair, Robert Wołk	4
15	Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel 2023 ·Dermatology and Therapy ·Kim Papp, Barbara Melosky, Sandeep Sehdev, Sébastien J. Hotte, Jennifer Beecker, Mark G. Kirchhof, Irina Turchin, Jan Dutz, Melinda Gooderham, Robert Gniadecki, Chih-ho Hong, Jo Lambert, Charles Lynde, Vimal H. Prajapati, Ronald Vender	10
16	Checklist for the Systemic Treatment of Psoriasis Using Biologics: A Delphi Study 2019 ·Journal of Cutaneous Medicine and Surgery ·Christine Fahim, (unknown), Marc Bourcier, Steven J. Glassman, Melinda Gooderham, Lyn Guenther, Wayne Gulliver, Charles Lynde, Yves Poulin, Melanie D. Pratt, Neil H. Shear, Ronald Vender, Scott R. Walsh, (unknown)	2
17	Non-melanoma Skin Cancer in Canada Chapter 1: Introduction to the Guidelines 2015 ·Journal of Cutaneous Medicine and Surgery ·Lyn Guenther, Kirk Barber, Gordon E. Searles, Charles Lynde, Peter M. Janiszewski, John Ashkenas	7
18	Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial 2008 ·British Journal of Dermatology ·Thomas Ruzicka, Charles Lynde, Gregor B. E. Jemec, Thomas L. Diepgen, J. Berth‐Jones, Pieter‐Jan Coenraads, Andrzej Kaszuba, Robert Bissonnette, E. Varjonen, Péter Holló, F. Cambazard, M. Lahfa, Peter Elsner, Fredrik Nyberg, Åke Svensson, Thomas C. Brown, (unknown), J. Maares	235
19	Recalcitrant necrobiotic xanthogranuloma responding to infliximab 2005 ·Journal of the American Academy of Dermatology ·J. Kraft, (unknown), Charles Lynde	3
20	Multiple melanomas occurring in a patient with xeroderma pigmentosum 1984 ·Journal of the American Academy of Dermatology ·(unknown), Charles Lynde, David I. McLean, William D. Stewart	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact